NCT03638180View on ClinicalTrials.gov

BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food Effect

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

July 9, 2018

Primary Completion Date

October 25, 2018

Study Completion Date

October 25, 2018

Conditions
Cough
Interventions
DRUG

BLU-5937

BLU-5937 oral tablet

DRUG

Placebo

Matching placebo to BLU-5937

Trial Locations (1)

H3P 3P1

Alta Sciences Algorithme Pharma, Mount Royal

All Listed Sponsors
lead

Bellus Health Inc. - a GSK company

INDUSTRY

NCT03638180 - BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food Effect | Biotech Hunter | Biotech Hunter